Compositions for stimulation of mammalian innate immune resistance to pathogens

Patent metadata

Field	Value
Publication number	US-10722573-B2
Application number	US-201615355530-A
Country	US
Kind code	B2
Filing date	Nov 18, 2016
Priority date	Mar 25, 2009
Publication date	Jul 28, 2020
Grant date	Jul 28, 2020

Abstract

Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a StIR composition to the individual.

First claim

The invention claimed is:

1. A composition comprising: (a) PAM2CSK4 lipopeptide, (b) a type C ligodeoxynucleotide (ODN), and (c) an antiviral pharmaceutical that inhibits viral replication or synthesis, viral protease activity, or cleaves viral nucleic acid, wherein the composition does not further comprise an active ingredient that is an antigen.

2. The composition of claim 1 , wherein the oligodeoxynucleotide (ODN) is ODN2395 or ODNM362 or ODN10101.

3. The composition of claim 1 , wherein the antiviral pharmaceutical is oseltamivir or ribavirin.

4. The composition of claim 1 , wherein the composition is formulated for administration to the lungs.

5. A method of treating, inhibiting, or attenuating a viral infection comprising administering an effective amount of the composition of claim 1 to an individual that has or is at risk of viral infection.

6. The method of claim 5 , wherein the subject has been exposed to a virus.

7. The method of claim 5 , wherein the virus is a Adenoviridae, Coronaviridae, Filoviridae, Flaviviridae, Hepadnaviridae, Herpesviridae, Orthomyxoviridae, Paramyxovirinae, Pneumovirinae, Picomaviridae, Poxyiridae, Retroviridae, or Togaviridae.

8. The method of claim 5 , wherein the virus is Influenza, H5N1, Marburg, Ebola, Severe acute respiratory syndrome coronavirus (SARS-COV), yellow fever virus, human respiratory syncytial, or Vaccinia virus.

9. The method of claim 5 , wherein the composition is administered by nebulization.

10. The method of claim 5 , wherein the lipopeptide, immune stimulatory oligonucleotide and anti-viral drug are administered in an amount of from about 0.1 mg/kg to about 100 mg/kg of the individual's body weight.

11. A nebulizer comprising (a) TLR2/6 lipopeptide, (b) TLR9 oligodeoxynucleotide (ODN), and (c) anti-viral pharmaceutical that inhibits viral replication or synthesis, viral protease activity, or cleaves viral nucleic acid, wherein the TLR2/6 lipopeptide is PAM2CSK4 and the TLR9 oligodeoxynucleotide (ODN) is a type C oligodeoxynucleotide (ODN).

12. The nebulizer of claim 11 , wherein the antiviral pharmaceutical is oseltamivir or ribavirin.

Assignees

• Univ Texas

Inventors

• Dickey Burton
• Tuvim Michael
• Evans Scott

Classifications

• A61K9/0078 Primary

  for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions · CPC title

• A61K38/08

  Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K31/7125

  Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters · CPC title

• A61P31/22

  for herpes viruses · CPC title